Clinical Trial Update: Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating paricalcitol for calcitriol-resistant secondary hyperparathyroidism in dialysis patients was terminated, with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Hyperparathyroidism

Drugs mentioned

• Paricalcitol (paricalcitol)

Snippet

Sponsor: Abbott | Conditions: Secondary Hyperparathyroidism, Dialysis | Phase 4 | Status: TERMINATED | Results posted: 2010-08-18